Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Talati, Naasha J ^a   Gonzalez Diaz, Esteban ^b   Mutemba, Charles ^c   Wendt, Joyanna ^d   Kilembe, William ^c   Mwananyanda, Lawrence ^c   Chomba, Elwyn ^c   Allen, Susan ^c,e   Del Rio, Carlos ^d,e   Blumberg, Henry M ^d,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c Zambia Emory HIV Research Project   (Zambia)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; TUBERCULIN TEST; ZAMBIA; EVALUATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEXUALITY;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEXUAL PARTNERS; TUBERCULIN TEST; YOUNG ADULT; ZAMBIA;

EID: 80053376541     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-264     Document Type: Article

References (33)

1. World Health Organization Report of the Third Global TB/HIV Working Group meeting: 'Two diseases -- one patient'. 2003, WHO, Geneva, World Health Organization.
2. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006, 100:415-31. 10.1179/136485906X91477, 16899146.
3. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-37. 10.1016/S0140-6736(06)68383-9, 16546541.
4. http://www.who.int/tb/publications/global_report/en/index.html
5. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, Taelman H, Van de Perre P, Serufilira A, Bogaerts J. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992, 146(6):1439-44.
6. American Thoracic Society and Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49(RR-6):1-51. American Thoracic Society and Centers for Disease Control and Prevention.
7. Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005, 293:2776-2784. 10.1001/jama.293.22.2776, 15941808.
8. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-50. 10.1056/NEJM198903023200901, 2915665.
9. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995, 274:143-148. 10.1001/jama.274.2.143, 7596002.
10. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-72. 10.1016/0140-6736(93)91817-6, 8101302.
11. Institute of Medicine Ending neglect: the elimination of tuberculosis in the United States. 2000, Washington, DC: National Academy Press, Institute of Medicine.
12. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4:761-76. 10.1016/S1473-3099(04)01206-X, 15567126.
13. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006, 6:413-22. 10.1586/14737159.6.3.413, 16706743.
14. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54(RR-15):49-55.
15. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M: tuberculosis specific interferon-gamma test. Respir Res 2006, 7:56. 10.1186/1465-9921-7-56, 1523341, 16579856.
16. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009, 10;9:15.
17. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an Interferon- Gamma Release Assay with Tuberculin Skin Testing in HIV-infected Individuals. Am J Respir Crit Care Med 2007, 175:737-742. 10.1164/rccm.200608-1088OC, 1899289, 17218620.
18. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007, 11(11):1190-5.
19. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, Morroni C, Mouton P, Diwakar L, Connell TG, Maartens G, Wilkinson RJ. Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007, 175:514-520.
20. Karam F, Mbow F, Fletcher H, Senghor CS, Coulibaly KD, LeFevre AM, Ngom Gueye NF, Dieye T, Sow PS, Mboup S, Lienhardt C. Sensitivity of IFN-gamma Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression. PLoS ONE 2008, 3:e1441. 10.1371/journal.pone.0001441, 2174527, 18197251.
21. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, Black GF, Beyers N, Walzl G. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008, 12(4):417-2.
22. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, Fideli U, Musonda R, Kasolo F, Gao F, Haworth A. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 2003, 17:733-40. 10.1097/00002030-200303280-00012, 12646797.
23. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F, Vermund SH, Aldrovandi GM. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001, 17(10):901-10. 10.1089/088922201750290023, 2748905, 11461676.
24. Modjarrad K, Zulu I, Karita E, et al. Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda. AIDS Res Hum Retroviruses 2005, 21(1):5-12. 10.1089/aid.2005.21.5, 15665639.
25. Peters PJ, Karita E, Kayitenkore K, Kancheya N, Funkhouser E, Allen S. HIV-infected Rwandan women have a high frequency of long-term survival. AIDS 2007, 21(Suppl 6):S31-7. 10.1097/01.aids.0000299408.52399.e1, 18032936.
26. Kempf MC, Allen S, Zulu I, Kancheya N, Stephenson R, Brill I, Tichacek A, Haworth A, Chomba E. Rwanda Zambia HIV Research Group. Enrollment and retention of HIV discordant couples in Lusaka, Zambia. J Acquir Immune Defic Syndr 2008, 47(1):116-25. 10.1097/QAI.0b013e31815d2f3f, 18030162.
27. Stephenson R, Barker J, Cramer R, Hall MA, Karita E, Chomba E, Vwalika C, Allen S. The demographic profile of sero-discordant couples enrolled in clinical research in Rwanda and Zambia. AIDS Care 2008, 20(3):395-405. 10.1080/09540120701593497, 18351489.
28. Duncan LE, Elliott AM, Hayes RJ, Hira SK, Tembo G, Mumba GT, Ebrahim SH, Quigley M, Pobee JO, McAdam KP. Tuberculin sensitivity and HIV-1 status of patients attending a sexually transmitted diseases clinic in Lusaka, Zambia: a cross-sectional study. Trans R Soc Trop Med Hyg 1995, 89:37-40. 10.1016/0035-9203(95)90649-5, 7747304.
29. Fisk TL, Hon HM, Lennox JL, Fordham von Reyn C, Horsburgh CR. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. Aids 2003, 17:1102-1104. 10.1097/00002030-200305020-00027, 12700468.
30. Markowitz N, Hansen NI, Wilcosky TC, et al. Pulmonary Complications of HIV Infection Study Group. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993, 119:185-193.
31. Graham NM, Nelson KE, Solomon L, Bonds M, Rizzo RT, Scavotto J, Astemborski J, Vlahov D. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992, 267:369-373. 10.1001/jama.267.3.369, 1727959.
32. Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, Ferrer E, Podzamczer D. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis 2011, 69(1):59-65. 10.1016/j.diagmicrobio.2010.09.005, 21146715.
33. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Golettie D, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J 2010, 35:619-626. 10.1183/09031936.00045509, 19608590.